Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Dr Reddy's,NPPA in...

    Dr Reddy's,NPPA in Court over drug price

    Written by Geeta Sharma Sharma Published On 2016-07-21T16:21:00+05:30  |  Updated On 21 July 2016 4:21 PM IST
    Dr Reddys,NPPA in Court over drug price

    New Delhi: Dr. Reddy’s in a petition in the Delhi High Court on July 19 has blamed the National Pharmaceutical Pricing Authority (NPPA), of having wrongfully revised the ceiling price of amlodipine, its high blood pressure and chest pain (Angina) treatment tablet.


    The NPPA has defended its stand stating that its decision stands correct in accordance with the provisions of the Drugs Price Control Order (DPCO) 2013.


    The company counsel stating facts said,"Under DPCO 2013, it is provided that the ceiling price (fixed) should be carried on for five years." . Amlodipine (5mg)'s ceiling price was last fixed in 2013, after which minor revisions were carried out as per the revised Wholesale Price Index (WPI), added the counsel.


    Arguing for a stay on NPPA’s decision to slash the drug’s price, Dr. Reddy’s counsel informed the court that the price of the drug had been slashed by 25% by the NPPA order dated May 9. He said the price revision had fixed Amlodipine’s ceiling price at Rs. 2.33 per tablet.


    Presenting further arguments, he said the government was exerting "uncharted" power to revise the prices of such drugs following the introduction of the amended National List of Essential Medicines 2015.


    Dr. Reddy’s has sought a stay because it can return the sum considered as overcharged to the government with interest, if it lost the case, while it would be at a loss for undercharging, if it won, explained the company counsel.


    Meanwhile, the NPPA has followed the due process as DPCO 2013 provides for a revision of the ceiling prices either five years from the date of fixing the ceiling price or as and when the NLEM is revised, said the government's counsel, Additional Solicitor General (ASG) Sanjay Jain.


    "Price revision done by NPPA in this case is exactly as per law and there is no ambiguity in this regard," NPPA Chairman, Bhupendra Singh, told the media.


    In June Dr Reddy's first moved a vacation bench at the High Court against NPPA's order. The company contributes Rs48.20 crore of the Rs326.30crore amlodipine (5mg) market with its brand Stamlo (5mg), according to pharmaceutical market research company AIOCD PharmaTrac.
    The price revision data of NPPA's shows the company holding the highest share (16.25%) of amlodipine (5mg)'s total Moving Annual Turnover (MAT).


    The drug maker refused to comment on the development, stating that the matter was subjudice


    Chief Justice G Rohini and Justice Sangita Dhingra Sehgal will continue hearing the case on July 22.


    AmlodipineBlood Pressure DrugChief Justice G RohiniDelhi high courtDPCODr Reddy'sDrugs Price Control OrderJustice Sangita Dhingra SehgalNational List of Essential Medicines 2015National Pharmaceutical Pricing AuthorityNPPAWholesale Price IndexWPI
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Geeta Sharma Sharma
    Geeta Sharma Sharma
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok